SerpApi.Org
Life sciences company Thermo Fisher (NYSE:TMO) announced in Q2 CY2026, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.
Is now the time to buy Thermo Fisher? Find out by accessing our full research report, it’s free.
Thermo Fisher (TMO) Q2 CY2026 Highlights:
・Revenue: $11.99 billion vs analyst estimates of $11.72 billion (10.5% year-on-year growth, 2.4% beat)
・Adjusted EPS: $6.03 vs analyst estimates of $5.71 (5.6% beat)
・Operating Margin: 17.4%, in line with the same quarter last year
・Free Cash Flow Margin: 14%, up from 10.2% in the same quarter last year
・Organic Revenue rose 5% year on year (beat)
・Market Capitalization: $195.6 billion
Company Overview
With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Thermo Fisher grew its sales at a tepid 3.9% compounded annual growth rate. This fell short of our benchmark for the healthcare sector and is a rough starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Thermo Fisher’s annualized revenue growth of 4.6% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.
Thermo Fisher also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Thermo Fisher’s organic revenue averaged 2.4% year-on-year growth. Because this number is lower than its two-year revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results.
This quarter, Thermo Fisher reported year-on-year revenue growth of 10.5%, and its $11.99 billion of revenue exceeded Wall Street’s estimates by 2.4%.
Looking ahead, sell-side analysts expect revenue to grow 6% over the next 12 months, similar to its two-year rate. This projection is above average for the sector and indicates its newer products and services will spur better top-line performance.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Adjusted Operating Margin
Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.
Thermo Fisher has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 23.4%.
Analyzing the trend in its profitability, Thermo Fisher’s adjusted operating margin decreased by 6.5 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.5 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
This quarter, Thermo Fisher generated an adjusted operating margin profit margin of 17.4%, down 4.5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Thermo Fisher, its EPS declined by 1.4% annually over the last five years while its revenue grew by 3.9%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
We can take a deeper look into Thermo Fisher’s earnings to better understand the drivers of its performance. As we mentioned earlier, Thermo Fisher’s adjusted operating margin declined by 6.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Thermo Fisher reported adjusted EPS of $6.03, up from $5.36 in the same quarter last year. This print beat analysts’ estimates by 5.6%. Over the next 12 months, Wall Street expects Thermo Fisher’s full-year EPS to grow 9.1% from $23.83 to $26.01.
Key Takeaways from Thermo Fisher’s Q2 Results
We enjoyed seeing Thermo Fisher beat analysts’ organic revenue expectations this quarter. We were also happy its revenue outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 4.2% to $547.90 immediately after reporting.
Thermo Fisher had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
